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a b s t r a c t
Many anticancer drugs act on cancer cells to promote apoptosis, which includes impairment of cellular
respiration (mitochondrial O2 consumption). Other agents also inhibit cellular respiration, sometimes
irreversibly. To investigate the sensitivity of cancer cells to cytotoxins, including anticancer drugs, we
compare the proﬁles of cellular O2 consumption in the absence and presence of these agents. Oxygen
measurements are made at 37 °C, using glucose as a substrate, with [O2] obtained from the phosphorescence decay rate of a palladium phosphor. The rate of respiration k is deﬁned as d[O2]/dt in a sealed container. Different toxins produce different proﬁles of impaired respiration, implying different mechanisms
for the drug-induced mitochondrial dysfunction. The decrease in the average value of k over a ﬁxed time
period, I, is proposed as a characteristic value to assess mitochondrial injury. The value of I depends on
the nature of the toxin, its concentration, and the exposure time as well as on the cell type. Results for
several cell types and 10 cytotoxins are presented here.
Ó 2008 Elsevier Inc. All rights reserved.

Although the process of drug-induced tumor cell death remains
poorly understood, many anticancer agents induce apoptosis
through similar mechanisms such as the release of cytochrome c
from mitochondria into cytosol and the consequent activation of
caspases. The activated caspases then attack the permeabilized
mitochondria, disrupt the mitochondrial electron transport chain,
collapse the mitochondrial inner membrane potential, and diminish
the mitochondrial structural integrity [1,2]. Interferences in the
apoptotic scheme reduce cancer cells’ sensitivity to therapy [3,4].
Because most anticancer drugs and other cytotoxic agents impair
mitochondria directly or indirectly, their cytotoxicity can be easily
assessed by measuring their effects on mitochondrial respiration.
It is proposed here that measurement of cellular respiration in the
presence and absence of an agent is a useful way to characterize
cytotoxicity. In the case of an anticancer drug, this measurement becomes an index of the cell’s sensitivity to treatment by the drug.
A variety of agents are studied here. The anthracycline antibiotic
doxorubicin intercalates with DNA and produces DNA breaks by
stimulating topoisomerase II cleavable complex formation [5]. In
the cell, the quinone moiety of doxorubicin is reduced to the semiquinone radical, generating reactive oxygen species that directly
damage cell organelles and induce apoptosis [6]. Dactinomycin is
an important anticancer chromopeptide that intercalates between
DNA base pairs and inhibits transcription [7]. Platinum (Pt)1 com* Corresponding author. Fax: +1 315 443 4070.
E-mail address: goodisma@mailbox.syr.edu (J. Goodisman).
1
Abbreviations used: Pt, platinum; tirapazamine, 3-amino-1,2,4-benzotriazine-1,4dioxide; CsA, cyclosporine A; MTP, mitochondrial transition permeability; Pd,
palladium; dH2O, distilled water; EDTA, ethylenediaminetetraacetic acid.
0003-2697/$ - see front matter Ó 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ab.2008.06.020

pounds, including cisplatin, carboplatin, oxaliplatin, and nedaplatin,
bind to DNA and promote apoptosis [8]. The latter three Pt agents differ from cisplatin (the parent compound) in the different ligands occupying the Pt coordination spheres. These structural variations yield
unique antitumor activity and toxicity proﬁles such as the reactivity
with DNA and induction of apoptosis [8]. Transplatin, the geometric
isomer of cisplatin, is expected to be less cytotoxic than cisplatin. Tirapazamine (3-amino-1,2,4-benzotriazine-1,4-dioxide) is a promising
agent that is effective in hypoxic tumor environments [9]. The activated compound results from a two-electron reduction of tirapazamine, which is readily reoxidized to its parent form in aerobic
conditions [10]. A highly cytotoxic hydroxyl radical (HO) is released
and produces DNA breaks, chromosomal aberrations, and eventually
cell death [9–11]. Not considered as an anticancer drug, cyclosporine
A (CsA) is an important immune suppressor. Its cellular targets include
cyclophilin and calmodulin, modulating calcium ﬂuxes through mitochondrial ion channel [12,13]. CsA decreases the possibility of mitochondrial transition permeability (MTP) induced by Ca2+
accumulation in the cytosol [14,15]. In addition, it blocks Ca2+ efﬂux
from mitochondria, causing calcium ﬂood in the mitochondrial matrix
that induces serious cytotoxicity and further injures mitochondrial
respiration [16]. Finally, caffeine is known to activate Ca2+ channels
on the plasma membrane and endoplasmic reticulum, rapidly accumulating Ca2+ in neighboring mitochondria, and this may impair their
function. Caffeine also potentiates the cytotoxicity of anticancer drugs.
The purpose of this work is to deﬁne a characteristic cytotoxicity parameter that will be useful in pharmacology and toxicology.
The parameter is the extent of inhibition of respiration, where inhibition is deﬁned in terms of the ratio of the average rates of
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respiration in the presence and absence of the cytotoxic agent.
Both rates must be measured on cells from the same batch because
rates depend on previous history and other uncontrollable factors.
It is expected that the rate of respiration in the presence of the
agent will depend on the agent’s nature, its concentration, and
the incubation time, as well as on the cell type, so that the inhibition will depend on all of these factors. For simplicity, the experiments discussed in this article are limited to two cell types:
Jurkat and HL-60.
Respiration rate is obtained from the decrease in dissolved
oxygen concentration in a closed vessel. Dissolved oxygen concentration is measured from the decay rate of phosphorescence
from a palladium phosphor, present in the solution, using a
homemade instrument [17–20]. In previous studies, we used this
instrument to explore the mitochondrial perturbation during
anticancer therapy in vitro as well as enzyme reactions involving
O2 [21–24]. The phosphorescence method of oxygen analysis has
several advantages compared with electrochemical and other
methods. It is totally noninvasive and does not affect the system
being measured because no oxygen is consumed by the measurement. It allows measurement of [O2] down to nanomolar
concentrations. It can be used continuously for long periods of
time with no deterioration (as for electrodes) or loss of accuracy,
so that slow processes such as decrease in respiration rates can
be followed. Furthermore, it requires only a single calibration,
with no necessity to check the instrument during or after long
runs.

Materials and methods
Reagents
Pd(II)
complex
of
meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin (sodium salt, palladium [Pd] phosphor) was obtained from Porphyrin Products (Logan, UT, USA). Its solution
(2.5 mg/ml = 2 mM) was prepared in distilled water (dH2O) and
stored at 20 °C in small aliquots.
Doxorubicin HCl (3.45 mM) was purchased from Bedford Laboratories (Bedford, OH, USA). Dactinomycin (actinomycin D, MW
1255.43) was purchased from Merck (Whitehouse Station, NJ,
USA); its solution was made fresh in dH2O, and its ﬁnal concentration was determined by absorbance at 440 nm using an
extinction coefﬁcient of 24,450 M1 cm1. Cisplatin (1 mg/ml,
3.3 mM in 154 mM NaCl) was purchased from American Pharmaceutical Partners (Schaumburg, IL, USA). Transplatin (yellow
powder, MW 300.05) was obtained from Sigma–Aldrich (St.
Louis, MO, USA) and dissolved as 1 mg/ml (3.3 mM) in 0.9%
NaCl. Carboplatin (MW 371.25) was purchased as 26.9 mM solution from Mayne Pharma (Paramus, NJ, USA). Oxaliplatin (MW
397.30) was purchased as 12.5 mM solution (50 mg oxaliplatin
in 10 ml of dH2O) from Central Pharmacy. Nedaplatin for injection (MW 303.18) was obtained from Tung Chit Pharmaceutical
(Nanjing, China); powder was freshly dissolved in 0.9% NaCl
(6.6 mM solution). CsA (MW 1202.64) was purchased from Bedford Laboratories as 41.6 mM solution (250 mg CsA in 5 ml of
33.2% absolute alcohol); a 1:1000 dilution in dH2O was made before each addition. Tirapazamine (MW 178.15) was obtained
from Sanoﬁ–Winthrop (Malvern, PA, USA); its solution was made
fresh in dH2O. NaCN solution (1.0 M) was freshly prepared in
dH2O; the pH was adjusted to approximately 7.0 with 12 N
HCl immediately prior to use. RPMI 1640 medium was purchased from Mediatech (Herndon, VA, USA). Caffeine powder
(MW 194.19) and remaining reagents were purchased from Sigma–Aldrich.

Cells
Human promyelocytic leukemia (HL-60) and T-cell lymphoma
(Jurkat) cells were purchased from American Tissue Culture Collection (Manassas, VA, USA). The cells were cultured in medium plus
10% fetal bovine serum, 1% l-glutamine, and 1% penicillin/streptomycin. Tu183 cells were obtained from Edward J. Shillitoe (State
University of New York, Upstate Medical University). They were
derived from a squamous cell carcinoma of the tonsil and were
highly resistant to therapy. The cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium nutrient mixture F-12 (Invitrogen, Carlsbad, CA, USA) plus 10% fetal bovine serum, 1% penicillin/streptomycin, and 0.2% primosin. For harvesting, the cells were
incubated at 37 °C in 2.5 ml of 0.05% (w/v) trypsin plus 0.53 mM
ethylenediaminetetraacetic acid (EDTA) for 5 min and then collected. Cell counts and viabilities were determined by light microscopy using a hemocytometer under standard trypan blue staining
conditions.
Cells were suspended at 0.5 to 1.0  106 cells/ml in medium
plus 2 lM Pd phosphor and 0.5% fat-free bovine serum albumin.
For each condition, 1.0 ml of the cell suspension was placed in a
1-ml glass vial (8-mm clear vials, Krackler Scientiﬁc, Albany, NY,
USA). The vial was sealed with a crimp top aluminum seal (using
a Wheaton hand crimper, Fisher Scientiﬁc) and placed in the
instrument for O2 measurement at 37 °C. Mixing was accomplished with the aid of parylene-coated stirring bars
(1.67  2.01  4.8 mm, V&P Scientiﬁc, San Diego, CA, USA).
O2 measurement
The O2 detection system was built to measure the phosphorescence of Pd phosphor as described previously [21,22]. DASYlab
(Measurement Computing, Norton, MA, USA) was used for data
acquisition. The data were analyzed by a C++ language computing
program [25] that calculated phosphorescence lifetime () and decay constant (1/s). Because oxygen quenches the phosphorescence,
the decay rate 1/s is a linear function of [O2] as

1=s ¼ 1=s0 þ kq ½O2 ;
where 1/s0, the decay rate in the absence of oxygen, was
10,087 ± 156 s1 and the value of the quenching rate constant, ks,
was 96.1 ± 1.2 lM1 s1 [21].
Index of respiration inhibition
Here we propose an index for the efﬁciency with which a chemical agent inhibits cellular respiration. The index can be calculated
from a graph of [O2] versus t when [O2] is measured in a closed
container because the negative of the slope, d[O2]/dt, is the respiration rate k (considered as a zero-order rate constant). For cells
not treated by cytotoxic agents, k is a constant, so that [O2] is a linear function of time,

½O2  ¼ ½O2 0  kt:

ð1Þ

The initial concentration of oxygen, [O2]o, can be calculated
from the Henry’s law constant for O2, assuming that the solution
is saturated with air ([O2]o is 225 lM for 37 °C). For cells treated
with most drugs, the value of k is time dependent; that is, [O2] does
not decrease linearly with time. Therefore, we propose to calculate
the average value of k over a ﬁxed time interval from experimental
measurements of [O2] versus t,

hki 

1
tf  ti

Z
ti

tf

kdt;
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and use hki as a measure of cytotoxicity. Because k = d[O2]/dt,

hki ¼

½O2 i  ½O2 f
tf  ti

ð2Þ

Because of the ﬂuctuations in measured [O2], one cannot simply
use the measured [O2] values at the end points of the interval to
calculate hki. Rather, one should use all of the measured values
in the calculation of hki.
To do this, we ﬁt all of the measurements to a suitable analytic
function and calculate [O2] at the end points from the parameterized function. A simple and convenient ﬁtting function is a secondorder polynomial, [O2] = a + bt + ct2. This is appropriate because it
includes the linear function as a special case, c = 0. With this function, k = (b + 2ct) and hki = b  c(ti + tf). It is expected that the
quadratic will be concave upward, corresponding to a gradual decrease in respiration rate, so that b will be negative and c will be
positive. More generally, a power series, [O2] = a + bt + ct2 + dt3
. . ., can be adopted. If the parameters c and d are small, [O2] versus
t will be a line; if not, it will be curved. The cubic term makes it
possible to represent a k that is nonmonotonic in time. Although
we have not found any cases where the ﬁt is improved signiﬁcantly
by going past the t2 term, this must be checked under speciﬁc circumstances. The average value of k for the cubic is

R tf

kdt

t

hki ¼ Ritf

dt

ti

¼

1
tf  ti

Z

tf

2

ðb þ 2ct þ 3dt Þdt

ti

¼ b  cðt f þ t0 Þ  dðt 2f þ t f t i þ t 2i Þ

ð3Þ

For all toxin-treated conditions, we choose tf  ti as a ﬁxed time
interval. Invariably, ti is longer than the preceding incubation time
by the time required for the sample preparation. In our experiments,
this time can vary from a few minutes to a half-hour, depending on
the number of sampling conditions, and is different for different
samples. However, this does not affect the calculation of hki given
that hki is an average over the same time period for all samples.
After the calculation of hki from ﬁtting of the experimental data
to a polynomial, we propose to calculate an index, I, deﬁned as

I ¼1




hki
;
hki0

ð4Þ

where hki is the average value of negative slope in the toxin-treated
condition and hki0 is the average value of negative slope in the untreated condition. The meaning of I is the average inhibition of cellular respiration due to the toxin treatment during the period when
measurements are made .If I depends on dosage D, experimentally
determined I values can be ﬁtted to the function


I¼


D
 Imax ;
AþD

ð5Þ

where Imax and A are constants for a particular drug and cell line.
When drug dosage reaches the concentration A, I equals half-maximal inhibition (Imax) of cellular respiration.
When a polynomial is used to ﬁt experimental [O2] for ti < t < tf,
it must be remembered that the polynomial has no validity outside
this region (e.g., [O2] certainly does not increase rapidly for later t
as a quadratic does). Because the polynomial cannot be used to
extrapolate to t = 0, it may be necessary to use the initial [O2]
(e.g., 225 lM at 37 °C). This information is added to the experimental points before ﬁtting.
Results
Dactinomycin and doxorubicin
We ﬁrst evaluated the impact of a prolonged exposure to dactinomycin or doxorubicin on cellular respiration. HL-60 cells

Fig. 1. (A) Effects of dactinomycin on cellular respiration. HL-60 cells (106 cells/ml)
were suspended in medium, 2 lM Pd phosphor, and 0.5% bovine serum albumin
with 10 lM dactinomycin (plus signs) or without drug (open circles). Time zero
corresponds to the addition of dactinomycin. The cells were then placed in the 37 °C
incubator. Aliquots (1.0 ml each) of untreated and treated cells were taken
periodically for [O2] measurement, performed every 30 s. Linear ﬁts were made
to the data for each condition (dashed lines for untreated cells, solid lines for
treated cells). (B) Effect of combined dactinomycin plus doxorubicin on cellular
respiration. Jurkat cells (0.5  106 cells/ml) were suspended in medium, 2 lM Pd
phosphor, and 0.5% albumin without drug addition (open circles) or with the
addition of 20 lM dactinomycin (open triangles), 20 lM doxorubicin (open
squares), or 10 lM dactinomycin + 10 lM doxorubicin (ﬁlled diamonds). Time zero
corresponds to the addition of drugs. Each vial was taken sequentially (every 60 s)
for respiration measurement. Linear ﬁts were made to the data for each condition
(dashed lines for cells untreated or treated with dactinomycin only, solid lines for
cells treated with doxorubicin or both drugs). (C) Effect of dactinomycin on cellular
respiration. Jurkat cells (0.5  106 cells/ml) were suspended in medium, 2 lM Pd
phosphor, and 0.5% albumin without drug addition (open circles) or with the
addition of 10 lM dactinomycin (ﬁlled triangles) or 20 lM dactinomycin (ﬁlled
diamonds). [O2] was measured alternately every minute on the three conditions.
Linear ﬁts to the data set for untreated cells are dashed lines, and quadratic ﬁts to
dactinomycin data sets are solid lines.
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(106 cells/ml) were suspended in medium, 2 lM Pd phosphor, and
0.5% bovine serum albumin without or with 10 lM dactinomycin.
The suspensions were then placed in the 37 °C incubator. Aliquots
(1.0 ml each) of untreated and treated cells were taken periodically
for [O2] measurement, with [O2] being determined every 30 s.
Measured [O2] is shown as a function of time in Fig. 1A (open circles for untreated cells, plus signs for treated cells). Time zero corresponds to the addition of dactinomycin or the beginning of
incubation. First, a sample of untreated cells was run for approximately 75 min, and then it was replaced by a sample of drug-treated cells that was run for approximately 50 min. Thereafter,
samples of untreated and treated cells were run. For each run, it
was found that [O2] decreased linearly with t, so [O2] versus t
was ﬁt to a line (dotted for untreated cells, solid for treated cells)
in each case.
The values of k for the two measurements on untreated cells, at 0
and 210 min, were 1.42 and 1.99 lM O2/min, respectively (r2 = 0.998
and 0.991, respectively). The increase in respiration rate with time
for untreated cells was attributed to cell growth. We assume that,
in the absence of drug, k for untreated cells increases linearly (i.e.,
k = 1.42 + (1.99  1.42)t/210), so that at 90, 150, and 270 min,
k = 1.66, 1.83, and 2.15 lM O2/min, respectively. The values of k for
the three measurements on treated cells (Fig. 1A) were 0.846,
0.642, and 0.639 lM O2/min (r2 = 0.993, 0.986, and 0.986), respectively. Thus, respiration was inhibited by 49% at 90 min, by 65% at
150 min, and by 70% at 270 min, showing that dactinomycin treatment caused progressive inhibition of respiration (see Table 1).
In another protocol, measurements of [O2] were made alternatively every 60 s on all of the samples (i.e., going to a different sample every 60 s) using the therapeutic drug doxorubicin as well as
dactinomycin. Jurkat cells (0.5  106 cells/ml) were suspended in
medium, 2 lM Pd phosphor, and 0.5% albumin without drug addition (open circles) or with the addition of 20 lM dactinomycin
(open triangles), 20 lM doxorubicin (open squares), or 10 lM dactinomycin plus 10 lM doxorubicin (ﬁlled diamonds) (Fig. 1B). Time
zero corresponds to the drug addition (beginning of incubation),

and measurements began at 50 min, so that incubation time was
50 min.
Linear ﬁts were made to the data for each condition (dashed
lines for untreated and dactinomycin-treated cells, solid lines for
doxorubicin-treated cells and cells treated with both drugs). The
slopes were 0.929 lM O2/min for untreated cells (r2 = 0.984),
0.732 lM O2/min for dactinomycin-treated cells (r2 = 0.996),
0.833 lM O2/min for doxorubicin-treated cells (r2 = 0.987), and
0.826 lM O2/min for the mixture (r2 = 0.995). Because deviations
from linearity were not evident, calculation of average k was
unnecessary. For the three conditions, respiration decreased by
21, 10, and 11%, respectively. The results show that for Jurkat cells,
dactinomycin is more potent than doxorubicin and the effect of
combining the two drugs is less than additive.
The advantages of this protocol include the ability to compare
multiple conditions (the same drug at different dosages or the
same dosage for various drugs) synchronously. Also, this protocol
requires fewer cells per condition, allowing lower rates of O2 consumption and, thus, longer measurement times that may permit
detection of deviations from linearity in [O2] versus t. Based on
the above experience, we adopted the latter protocol in most of
our experiments.
We previously reported [21] that [O2] versus t plots for cells
treated with doxorubicin were actually well ﬁt by two lines; that
is, k was constant and equal to the value for untreated cells for
approximately 150 min and then decreased to a lower value. The
results of Fig. 1B may show this discontinuity in slope. However,
this does not have a major effect on our conclusions given that
the k values from linear ﬁts, reported above, are average values
for the full time of measurement. In contrast to doxorubicin, dactinomycin produced nonlinear [O2] versus t plots that were concave
upward; that is, k decreased gradually with time [22]. Therefore,
dactinomycin data for long periods of time should be analyzed
using a polynomial model.
Fig. 1C shows [O2] versus t for 0.5  106 Jurkat cells/ml under
the same conditions as for Figs. 1A and 1B. Open circles represent

Table 1
Values of k for cisplatin-treated and untreated cells and r2 values
Condition

Cell type and
concentration

Drug

Concentration
(lM)

Incubation time
(min)

k (lM O2/min),
untreated

k (lM O2/min),
treated

Ratio of k
values

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

HL-60, 106/ml
HL-60, 106/ml
HL-60, 106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
Jurkat, 0.5  106/ml
HL-60, 0.5  106/ml
HL-60, 0.5  106/ml
HL-60, 0.5  106/ml
HL-60, 0.5  106/ml

Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Doxorubicin
Dactinomycin + doxorubicin
Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Dactinomycin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Doxorubicin
Dactinomycin
Dactinomycin
Doxorubicin
Doxorubicin

10
10
10
20
20
10 + 10
10
10
10
10
20
20
20
20
3
3
5
5
10
10
20
20
40
40
10
10
20
20

90
150
270
50
50
50
30
90
150
210
30
90
150
210
90
150
90
150
90
150
90
150
90
150
30
180
30
180

1.660
1.830
2.150
0.929
0.929
0.929
1.252
1.252
1.252
1.252
1.252
1.252
1.252
1.252
1.144
1.144
1.144
1.144
1.144
1.144
1.144
1.144
1.144
1.144
0.645
0.435
0.645
0.435

0.846
0.642
0.639
0.732
0.833
0.826
0.898
0.608
0.368
0.128
0.793
0.553
0.313
0.073
1.002
0.692
0.947
0.650
0.886
0.619
0.795
0.354
0.773
0.457
0.559
0.228
0.503
0.223

0.510
0.350
0.300
0.790
0.900
0.890
0.717
0.486
0.294
0.102
0.633
0.442
0.250
0.058
0.876
0.604
0.828
0.656
0.774
0.541
0.696
0.309
0.676
0.399
0.867
0.524
0.780
0.513
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untreated cells, ﬁlled triangles represent cells treated with 10 lM
dactinomycin, and ﬁlled diamonds represent cells treated with
20 lM dactinomycin. All of the data for untreated cells were well
ﬁt to a line (r2 = 0.994) as expected. The slope was 1.252 lM/
min, and the y intercept was 214.7 lM. The linear ﬁt for 10 lM
drug-treated cells is [O2] = 227.7 lM  (0.420 lM/min)t
(r2 = 0.982); for 20 lM drug-treated cells, [O2] = 198.6 lM 
(0.674 lM/min)t (r2 = 0.899). Obviously, both poor linear ﬁts show
that curvature is important, so that quadratic ﬁts (shown as solid
lines) are a big improvement. For 10 lM drug-treated cells, the
quadratic is [O2] = 221.0 lM  (1.088 lM/min)t + (0.002 lM/
min2)t2 (r2 = 0.998), so that b = 1.088 lM/min and c = 0.002 lM/
min2. For 20 lM drug-treated cells, [O2] = 259.6 lM  (1.003 lM/
min)t + (0.002 lM/min2)t2 (r2 = 0.972). We take ti = 30, 90, 150,
and 210 min and tf  ti = 60 min for all four cases. Then hki is calculated as b  c(ti + tf) for all eight cases, giving the results in Table 1 (lines 7–14). For each ti, the inhibition is greater for the higher
drug concentration; for each drug concentration, the inhibition increases with time.
The same method was employed to analyze the next experiments on doxorubicin-treated cells. Altered O2 consumption proﬁles due to treatment with doxorubicin at various doses are
shown in Fig. 2A. Here 0.5  106 Jurkat cells/ml were treated with
0 lM doxorubicin (open circles), 3 lM doxorubicin (open triangles), 5 lM doxorubicin (open squares), 10 lM doxorubicin (ﬁlled
triangles), 20 lM doxorubicin (ﬁlled diamonds), and 40 lM doxorubicin (ﬁlled squares). For all drug-treated conditions, [O2] was
measured out to 200 min. The point at t = 0, [O2] = 225 lM, calculated for air-saturated dH2O, was added to the measured points.
As shown in Fig. 2A, the O2 consumption proﬁles for doxorubicin-treated conditions were ﬁtted to quadratic forms, and the proﬁle for untreated cells was ﬁtted to a line (constant k value). The
value of k for untreated cells, the negative of the slope of the
best-ﬁt line, was 1.144 lM/min (r2 = 0.988).
For cells treated with 3, 5, 10, 20, or 40 lM doxorubicin, leastsquares ﬁtted to quadratics, the values of the linear and quadratic
coefﬁcients b and c were as follows: for 3 lM drug, b = 1.504 and
c = 0.0022 (r2 = 0.996); for 5 lM drug, b = 1.341 and c = 0.0016
(r2 = 0.998); for 10 lM drug, b = 1.420 and c = 0.0022
(r2 = 0.988); for 20 lM drug, b = 1.681 and c = 0.0037
(r2 = 0.988); for 40 lM drug, b = 1.406 and c = 0.0026
(r2 = 0.979). Values of hki were then calculated from the quadratic
forms, with ti = 30, 90, 150, and 210 min and tf  ti = 60 min, as for
dactinomycin. The values are given in Table 1 for ti = 90 and
150 min only. This is sufﬁcient because if a single quadratic is used
to ﬁt all of the data for [O2] versus t, hki will be a linear function of ti
so long as tf  ti is kept constant.
Calculated inhibitions (values of I) are plotted in Fig. 2B. It
should be noted that results for 40 lM doxorubicin are less reliable
than results for other concentrations because d[O2]/dt becomes
zero (100% inhibition) before the time of measurement, which is
200 min. Also shown in Fig. 2B is the best ﬁt (r2 = 0.933) of I to
Eq. (5). The best values for Imax and A are 0.735 and 3.27 lM,
respectively. We also ﬁtted to Eq. (5) with Imax = 1 (i.e., 100% inhibition) and found the best value of A (8.45 M). However, the low
value of r2 (0.817) indicated that the latter ﬁtting was not suitable.
The results presented so far indicate that dactinomycin is
approximately twice as potent as doxorubicin for Jurkat cells; that
is, to get comparable inhibition of respiration, doxorubicin must be
used at twice the concentration of dactinomycin. We next investigated the effect of these two drugs on HL-60 cell respiration. We
incubated 0.5  106 HL-60 cells/ml in open containers without or
with 10 lM dactinomycin or 20 lM doxorubicin. A 1.0-ml aliquot
for untreated and treated cells was taken every 150 min for O2
measurement. Fig. 2C shows the results for untreated cells (open
circles), 10 lM dactinomycin-treated cells (ﬁlled triangles), and
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20 lM doxorubicin-treated cells (ﬁlled squares). The incubation
time for each set of measurements is the time of the ﬁrst measurement (i.e., 30 min for the ﬁrst three runs and 180 min for the second three runs). Because each set of measurements was over a
limited time, the k values were obtained from the best linear ﬁts.
At t = 30 min, k = 0.645 lM O2/min for untreated cells (r2 = 0.993),
0.559 lM O2/min for dactinomycin-treated cells (r2 = 0.989), and
0.503 lM O2/min for doxorubicin-treated cells (r2 = 0.989); at
t = 180 min, k = 0.435 lM O2/min for untreated cells (r2 = 0.996),
0.228 lM O2/min for dactinomycin-treated cells (r2 = 0.967), and
0.223 lM O2/min for doxorubicin-treated cells (r2 = 0.903). Thus,
after 30 min incubation, dactinomycin inhibited HL-60 cell respira-

Fig. 2. (A) Measurement of respiration rate. Jurkat cells (0.5  106 cells/ml) were
suspended in medium, 2 lM Pd phosphor, and 0.5% bovine serum albumin without
drug treatment (open circles) or with treatment with 3 lM doxorubicin (open
squares), 5 lM doxorubicin (open triangles), 10 lM doxorubicin (ﬁlled triangles),
20 lM doxorubicin (ﬁlled diamonds), or 40 lM doxorubicin (ﬁlled squares).
Quadratic ﬁts for all doxorubicin-treated conditions are shown as indicated; the
data for untreated cells were ﬁt to a line. The respiration rates are obtained as the
negative derivatives, k = d[O2]/dt. (B) Values of average k at 150 min incubation
were calculated from the quadratic ﬁts (linear ﬁt for untreated cells), and inhibition
I was calculated for each concentration. Values of I are plotted versus [doxorubicin]
(ﬁlled squares) and compared with best-ﬁt function (line). The function is I = ImaxD /
(A + D), where D is drug concentration, Imax = 0.735, and A = 3.27 lM (r2 = 0.933). (C)
HL-60 cells (0.5  106 cells/ml) were suspended in medium, 2 lM Pd phosphor, and
0.5% albumin without drug treatment (open circles) or with treatment with 10 lM
dactinomycin (ﬁlled triangles) or 20 lM doxorubicin (ﬁlled squares). Time zero
corresponds to the addition of drugs. Aliquots (1.0 ml each) of untreated and
treated samples were taken every 150 min for O2 measurement. Dashed lines show
the best linear ﬁts for untreated cell respiration.
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tion by 13.3%, whereas doxorubicin inhibited respiration by 22.0%;
after 180 min incubation, dactinomycin inhibited cell respiration
by 47.6%, whereas doxorubicin inhibited respiration by 48.8%.
Thus, dactinomycin is twice as potent as doxorubicin for HL-60
cells as well as for Jurkat cells.
There is an apparent decrease in the respiration rate for untreated cells with time (k = 0.645 at 30 min and 0.435 at
180 min), possibly due to problems with maintenance of the cell
culture. Day-to-day variations are likely even more important than
intraday variations. This underlines the importance of always comparing measured k for treated cells with k for untreated cells from
the same batch measured over the same time period, as we did
here.
Pt compounds
We next investigated the effects of Pt compounds on the respiration of Jurkat cells. Fig. 3A shows results of one experiment in
which 106 cells/ml were untreated (open circles) or were treated
with 20 lM cisplatin (ﬁlled squares), carboplatin (ﬁlled triangles),
oxaliplatin (ﬁlled diamonds), or nedaplatin (ﬁlled circles) or with
10 mM NaCN (crosses). The values of k were obtained from the best
linear ﬁts and were as follows (means ± standard deviations from
the best linear ﬁts): 1.54 ± 0.05 lM O2/min for untreated cells
(r2 > 0.984), 1.66 ± 0.05 lM O2/min for cisplatin-treated cells

(r2 > 0.987), 1.50 ± 0.06 lM O2/min for carboplatin-treated cells
(r2 > 0.977), 1.53 ± 0.06 lM O2/min for oxaliplatin-treated cells
(r2 > 0.980), 1.61 ± 0.07 lM O2/min for nedaplatin-treated cells
(r2 > 0.976), and 0.27 ± 0.05 lM O2/min for the cyanide-treated
condition (r2 > 0.660). Thus, the average rate of cellular respiration
under treatment of different Pt drugs was 1.58 ± 0.07 lM O2/min,
which was the same as that for individual drugs within statistical
error. Furthermore, the rate of respiration for drug-treated cells
was not statistically different from the rate for untreated cells
within statistical error. The plots for the drug-treated cells showed
no systematic deviation from linearity, conﬁrming that none of the
drugs inhibited respiration during the 100 min when [O2] was
measured. In contrast, the addition of NaCN inhibited cellular respiration 82.5% during the 100 min incubation. On performing the
same experiments with all of the Pt compounds but changing the
cell line to Tu183 and HL-60 cells, similar results were observed;
that is, there was no inhibition occurring in Pt drug-treated cell
respiration after approximately 2 h exposure.
The next experiment was performed to conﬁrm and extend the
above observations. Jurkat cells (0.5  106 cells/ml) were incubated without or with 40 lM cisplatin. Aliquots (1.0 ml each) from
untreated and treated samples were taken every 180 min for O2
measurement. Fig. 3B shows the results for untreated cells (open
circles) and 40 lM cisplatin-treated cells (ﬁlled squares), with
the dashed lines being the best linear ﬁts for untreated cells. The

Fig. 3. Effects of Pt compounds on Jurkat cells. Jurkat cells (0.5–1.0  106 cells/ml) were suspended in medium containing 2 lM Pd phosphor and 0.5% bovine serum albumin.
(A) Here 1.0  106 Jurkat cells/ml were untreated (open circles) or were treated with 20 lM cisplatin (ﬁlled squares), 20 lM carboplatin (ﬁlled triangles), 20 lM oxaliplatin
(ﬁlled diamonds), or 20 lM nedaplatin (ﬁlled circles) or with 10 mM NaCN (crosses). Linear ﬁts for all conditions are shown as dashed lines. (B) Here 0.5  106 Jurkat cells/ml
were untreated (open circles) or were treated with 40 lM cisplatin (ﬁlled squares). Time zero corresponds to the addition of drugs. Aliquots (1.0 ml) of untreated and treated
samples were taken every 3 h for O2 measurement. Dashed lines indicate the best linear ﬁts for untreated cell respiration. (C) Here 0.5  106 Jurkat cells/ml were untreated
(duplicates, open or ﬁlled circles) or were treated with 20 or 40 lM cisplatin (open or ﬁlled triangles) or 20 or 40 lM transplatin (open or ﬁlled squares). Time zero
corresponds to the addition of drugs. After 12 h incubation, 1.0-ml aliquots of untreated and treated samples were taken every 60 or 90 min for O2 measurement. All of the k
values, obtained from the best linear ﬁts, are given in Table 2. (D) All of the k values (in lM O2/min) in Table 1 are plotted versus incubation time before sampling. Duplicate
results for untreated cells are open or ﬁlled circles connected by lines, results for cells treated with 20 or 40 lM cisplatin are open or ﬁlled triangles, and results for cells
treated with transplatin are open or ﬁlled squares. Time zero corresponds to the addition of drugs; cells were continuously exposed up to the time of sampling for O2
measurements.
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Table 2
Values of k for cisplatin-treated and untreated cells and r2 values
Condition

Untreated 1
Untreated 2
20 lM cisplatin
40 lM cisplatin
20 lM transplatin
40 lM transplatin

k (lM O2/min)
12.0 h exposure

13.5 h exposure

14.5 h exposure

15.5 h exposure

16.5 h exposure

17.5 h exposure

1.80
(0.962)
1.59
(0.974)
1.68
(0.987)
1.36
(0.992)
1.61
(0.960)
1.80
(0.951)

2.19
(0.972)
2.00
(0.951)
1.81
(0.979)
1.07
(0.947)
1.81
(0.969)
2.06
(0.989)

2.05
(0.963)
2.11
(0.985)
2.32
(0.977)
1.54
(0.966)
2.54
(0.972)
2.08
(0.961)

2.33
(0.985)
2.22
(0.975)
2.37
(0.975)
1.45
(0.992)
2.41
(0.987)
2.29
(0.973)

2.32
(0.983)
2.08
(0.968)
2.70
(0.950)
1.31
(0.989)
2.64
(0.990)
2.27
(0.966)

2.26
(0.958)
2.34
(0.974)
1.49
(0.960)
0.71
(0.988)
2.57
(0.975)
2.47
(0.986)

Note: r2 values are in parentheses.

k values were as follows: at t = 0 min, 0.666 lM O2/min for untreated cells (r2 = 0.987) and 0.690 lM O2/min for cisplatin-treated
cells (r2 = 0.992); at t = 180 min, 0.572 lM O2/min for untreated
cells (r2 = 0.983) and 0.580 lM O2/min for cisplatin-treated cells
(r2 = 0.991); at t = 440 min, 0.354 lM O2/min for untreated cells
(r2 = 0.990) and 0.343 for cisplatin-treated cells (r2 = 0.936). Here
again, the respiration rates in untreated cells decline as time
elapses. However, there is no statistically signiﬁcant difference in
cellular O2 consumption rates between treated and untreated cells
for up to 6 h continuous exposure to 40 lM cisplatin.
In the next series of experiments, we incubated Jurkat cells
(0.5  106 cells/ml) suspended in medium (containing 2 lM Pd
phosphor and 0.5% bovine serum albumin) with 20 or 40 lM cisplatin for 12 h. At the same time, a culture of the same cells was
maintained with no cisplatin added and, as a further control, a culture of the same cells was incubated with 20- or 40-lM concentrations of transplatin. After 12 h, aliquots (1.0 ml each) of untreated
and treated samples were taken periodically for O2 measurement.
To check reproducibility, duplicate samples were taken of the untreated cells. Oxygen measurements were stopped and a new set of
aliquots was taken when [O2] in a sample of untreated cells
reached 50 lM. This almost always meant a new set every hour.
Results are shown in Fig. 3C.
The k values obtained from the best linear ﬁts are shown in Table 2 and plotted versus sampling start time (which is equal to
incubation time) in Fig. 3D. It is clear that k values in duplicate untreated cell samples (open or ﬁlled circles, connected by lines) stay
close to each other, conﬁrming that the measurements are consistent and repeatable. Overall, k values for untreated cells increase
with time. The increase in k with time is ascribed to cell growth.
Cells treated with 20 lM transplatin (open squares) or 40 lM
transplatin (ﬁlled squares) show no difference from the untreated
cells, suggesting that 18 h continuous exposure to transplatin has
no inhibitory effect on cellular respiration.
For 20 lM cisplatin-treated cells, respiration rate remained
similar to that for untreated cells up to 17 h and then decreased.
This result agrees with a previous study on cisplatin-induced caspase activation in Jurkat cells, where caspase activity started at
14 h incubation with 20 lM cisplatin [23]. For 40 lM cisplatintreated Jurkat cells, respiration rates appear to be signiﬁcantly lower than those for untreated cells after 12 h, implying that the inhibition of mitochondrial O2 consumption occurred earlier for the
higher concentration. The decrease in respiration is more marked
after 15 h. The inhibition I may be calculated as 1 minus the ratio
of k for treated cells to k for untreated cells (with the average of
two values being used for untreated cells). Then, for the incubation
times in Table 3, the values of I with 20 lM cisplatin are 0.01, 0.14,
0.12, 0.04, 0.23, and 0.35. For 40 lM cisplatin, I = 0.20, 0.48,

0.26, 0.36, 0.40, and 0.69. These results reﬂect a dose-dependent
and time-dependent inhibition of cellular respiration by cisplatin,
whereas there is no observable impairment by the trans-isomer.
Tirapazamine
We ﬁrst studied the effect of tirapazamine in low concentrations (0–15 lM) on HL-60 cell respiration, with 0.5  106 cells/ml
being incubated with 0, 1, 3, 5, 10, and 15 lM drug. Fig. 4A shows
the respiratory proﬁles for untreated cells (open circles) and for
cells treated with 1 lM tirapazamine (ﬁlled squares), 3 lM tirapazamine (ﬁlled triangles), 5 lM tirapazamine (ﬁlled diamonds),
10 lM tirapazamine (ﬁlled circles), or 15 lM tirapazamine (open
squares) in 3 h exposure. Results for untreated cells were ﬁtted
to a line with a slope of 0.487 lM/min (best linear ﬁtting, dashed
line). Results for treated cells, which did not suggest curvature,
were also ﬁtted to lines. Quadratic ﬁtting improves r2 only in the
fourth decimal place. The k values obtained from the best linear ﬁts
for 0, 1, 3, 5, 10, and 15 lM tirapazamine (r2 = 0.995, 0.935, 0.986,
0.966, 0.974, and 0.991, respectively) are given in the ﬁrst six lines
of Table 3. There is no statistically signiﬁcant trend in the values of
hki/hko i, although they are all signiﬁcantly lower than unity. Thus,
the effect of tirapazamine at these concentrations is too small to be
accurately measured.
To study the effect of higher concentrations of tirapazamine on
HL-60 cell respiration, 106 cells/ml were incubated with various
concentrations of the drug for 3 h. Fig. 4B shows O2 consumption

Table 3
Average respiration rates for tirapazamine-treated HL-60 cells
[Drug] (lM)

Incubation time (min)

hki (lM/min)

hki/hkio

0
1
3
5
10
15
0
0
50
50
100
100
200
200
500
500
1000
1000

90
90
90
90
90
90
90
150
90
150
90
150
90
150
90
150
90
150

0.4870
0.3750
0.3820
0.3960
0.3740
0.4300
0.6444
0.3745
0.5770
0.2454
0.5356
0.2937
0.5967
0.3419
0.5180
0.2084
0.4106
0.2223

—
0.770
0.784
0.811
0.768
0.883
—
—
0.895
0.655
0.831
0.784
0.926
0.913
0.804
0.749
0.637
0.594
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assumes that all solutions were initially saturated with air at
37 °C. Then results for untreated cells were ﬁtted to a line
[O2] = 187.5 lM  (0.713 lM/min)t (r2 = 0.949). Because of the
low value of r2, results for untreated cells were ﬁtted to a quadratic
as with results for treated cells. The values of r2 were then 0.974 for
no tirapazamine and 0.991, 0.987, 0.981, 0.971, and 0.951 for 50,
100, 200, 500, and 1000 lM tirapazamine, respectively.
Values of hki were calculated according to Eq. (3) with d = 0 and
tf  ti = 60 min. The results are shown in Table 3, which gives hki
only for ti = 90 and 150 min. Because all O2 consumption proﬁles
were ﬁtted to quadratic forms, hki is a linear function of ti. For
the calculation of hki/hkio , the value of hkio is taken from this set
of runs, not the previous set. The inhibitions of cellular respiration
I at 90 min incubation were 10.5, 16.9, 7.4, 19.6, and 37.3% for
treatment with 50, 100, 200, 500, and 1000 lM tirapazamine,
respectively. (Results for 90 min are used here because 90 min is
in the middle of the range of data being ﬁtted.) As shown in
Fig. 4C, these data were ﬁtted to Eq. (5); the best ﬁt had Imax = 0.61
and A = 751 lM (r2 = 0.760). Assuming that Imax = 1 (i.e., 100% inhibition) led to a much worse ﬁt with A = 1696 lM (r2 = 0.749).
CsA
To investigate the effect of CsA on mitochondrial O2 consumption, we incubated Jurkat cells (106 cells/ml) with CsA and measured oxygen concentrations alternately on ﬁve conditions. As
shown in Fig. 5A, the ﬁve conditions were as follows: without drug
(open circles) and with 20 nM CsA (ﬁlled triangles), 50 nM CsA
(ﬁlled diamonds), 200 nM CsA (ﬁlled circles), or 500 nM CsA (ﬁlled
squares). Because there was no evident curvature in these plots, all
O2 consumption proﬁles were ﬁtted to linear functions. Thus, for
[CsA] = 0, 20, 50, 200, and 500 nM, linear ﬁts (r2 = 0.989, 0.985,

Fig. 4. Effects of tirapazamine on cellular respiration of. HL-60 cells suspended in
medium containing 2 lM Pd phosphor and 0.5% bovine serum albumin. (A) HL-60
cells (0.5  106 cells/ml) were incubated without drug (open circles) or with 1 lM
tirapazamine (ﬁlled squares), 3 lM tirapazamine (ﬁlled triangles), 5 lM tirapazamine (ﬁlled diamonds), 10 lM tirapazamine (ﬁlled circles), or 15 lM tirapazamine
(open squares). Linear ﬁts are shown for both untreated (solid line) and tirapazamine-treated conditions. (B) HL-60 cells (106 cells/ml) were incubated without
drug (open circles) or with 50 lM tirapazamine (ﬁlled squares), 100 lM tirapazamine (ﬁlled triangles), 200 lM tirapazamine (ﬁlled diamonds), 500 lM tirapazamine (ﬁlled circles), or 1.0 mM tirapazamine (open squares). Linear ﬁts for
untreated and quadratic ﬁts for tirapazamine-treated cells are shown as indicated.
For treated cells, the point at t = 0 was added. (C) Values of calculated I are plotted
versus tirapazamine concentration (ﬁlled squares). Values of I are also ﬁtted to Eq.
(4) using least-squares error (solid line).

proﬁles for untreated cells (open circles) and for cells treated with
50 lM tirapazamine (ﬁlled squares), 100 lM tirapazamine (ﬁlled
triangles), 200 lM tirapazamine (ﬁlled diamonds), 500 lM tirapazamine (ﬁlled circles), or 1 mM tirapazamine (open squares). Results for untreated cells were ﬁtted to a line (r2 = 0.996) with a
slope of 0.637 lM/min (dashed line shown in Fig. 4B). Results
for treated cells, which showed obvious curvature, were ﬁtted to
quadratics (r2 = 0.992, 0.986, 0.973, 0.975, and 0.934 for 50, 100,
200, 500, and 1000 lM tirapazamine, respectively). To the results
for each condition was added one point, [O2]o = 225 lM, which

Fig. 5. Effects of CsA on cellular respiration. (A) Jurkat cells (106 cells/ml) were
suspended in medium, 2 lM Pd phosphor, and 0.5% bovine serum albumin and
were incubated without drug (open circles) or with 10 nM CsA (ﬁlled triangles),
50 nM CsA (ﬁlled diamonds), 200 nM CsA (ﬁlled circles), or 500 nM CsA (ﬁlled
squares). Linear ﬁts to the respiration proﬁles are shown as dashed lines. (B) Values
of calculated inhibition I are plotted versus CsA concentration (ﬁlled squares).
Values of I are also ﬁtted to a function of least-squares error (solid line).
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Fig. 6. Effects of caffeine on cellular respiration. HL-60 cells (106 cells/ml) were suspended in medium, 2 lM Pd phosphor, and 0.5% bovine serum albumin and were incubated in
the presence or absence of caffeine. (A) Caffeine concentrations were 0.1 mM (ﬁlled circles), 0.5 mM (open diamonds), 1.0 mM (open squares), and 2.0 mM (ﬁlled triangles). Best
linear ﬁts are shown for all four conditions. (B) Oxygen concentrations were measured for approximately 40 min with no caffeine present, at which point caffeine was injected.
Results of two separate experiments are shown, with least-squares ﬁts before and after caffeine injection. In the ﬁrst experiment (open and ﬁlled triangles with dashed line for
ﬁts), caffeine concentration was 2.0 mM. In the second experiment (open and ﬁlled circles with solid line for ﬁts), caffeine concentration was 3.0 mM. (C) Inhibition I = 1  k/ko
calculated from respiration rates derived from experiments in panels A and B. Shown is best-ﬁt straight line for I versus caffeine concentration.

0.984, 0.984, and 0.975, respectively) gave hki = k = 1.10, 1.03, 0.99,
0.89, and 0.83 lM O2/min, respectively. (By putting 225 lM as the
initial oxygen concentration [O2]o and adopting quadratic ﬁtting, r2
values became worse (0.950, 0.969, 0.967, 0.965, and 0.966,
respectively). It is clear from these results that the inhibitory effect
of CsA on cellular respiration was dose dependent.
From the k values obtained from the linear ﬁtting, we calculated
I = 1  k/k0. Results are shown in Fig. 5B, with the best ﬁt to Eq. (5)
shown as a solid line and with Imax = 0.272 and A = 57.9 nM
(r2 = 0.994). When Imax = 1 (i.e., 100% inhibition) was assumed,
the best value of A turned out to be 1150.3 nM, but r2 = 0.598, so
this ﬁtting cannot be adopted.
Caffeine
We investigated the effect of pure caffeine (powder formulation
without vehicle) on HL-60 cellular respiration. The cells (106 cells/
ml) were suspended in medium plus 2 lM Pd phosphor and 0.5%
albumin with the addition of 0.1, 0.5, 1.0, or 2.0 mM caffeine. Caffeine was dissolved in the medium and added to the cell suspension immediately prior to O2 measurement. Measurements were
made alternately on the four samples. Results are shown in
Fig. 6A. Here k values were obtained from the slopes of the best linear ﬁts because going to quadratic ﬁts produced no improvement.
For the four concentrations of caffeine, we found k = 0.843, 0.726,
0.727, and 0.676 lM O2/min (r2 = 0.966, 0.941, 0.929, and 0.946,
respectively). From the four k values, linear extrapolation to 0 concentration produced k0 = 0.8090 ± 0.0364. This value of k0 was used
to calculate the inhibitions for the four concentrations, which were
0.042, 0.102, 0.101, and 0.165, respectively.
Fig. 6B shows results of two separate experiments to test
whether the effect of caffeine on HL-60 respiration was immedi-

ate. After O2 measurement proceeded for approximately 40 min,
caffeine was injected into the vials and O2 measurement was
continued. The results for 1 mM caffeine are shown by empty
and ﬁlled triangles in Fig. 2B, with best-ﬁt lines (before and after
caffeine addition) shown as dashed. The k value before addition
was 0.883 lM O2/min and was reduced instantly to 0.787 lM
O2/min after addition (11% inhibition). For 3.0 mM caffeine (data
not shown), the k value before addition was 1.028 lM O2/min
and was reduced instantly to 0.568 lM O2/min after addition
(45% inhibition).
All of the inhibitions from the experiments of Figs. 6A and 6B
are plotted versus caffeine concentration in Fig. 6C. Here I = 1 
k/ko. The best-ﬁt line is also shown; it comes very close to passing
through (0,0) as expected. There is no sign of saturation (i.e., leveling off in the plot of I vs. [caffeine]) in this range of concentrations,
so no attempt was made to ﬁt to Eq. (5).
Discussion
The use of respiratory monitoring is proposed here to assess the
extent of drug-impaired cellular function and how it depends on
parameters such as incubation time and dosage. To obtain respiration rates, we measure [O2] using phosphorescence decay (other
methods could also be used [26,27]). Although different drugs attack different cellular targets such as mitochondria, DNA, and thiols, their inhibitory effects on the mitochondrial function
sometimes appear to be similar. Clearly, answering the question
of why a particular drug gives a speciﬁc cellular respiration pattern
requires more understanding of the drug–cell interaction than is
currently available. However, differences in oxygen consumption
proﬁles (Figs. 1–6) indicate different mechanisms of action for dif-
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ferent drugs. The diverse proﬁles make it important to characterize
the drug effect by a single parameter such as the inhibition I.
To measure the extent of inhibition of mitochondrial oxygen
consumption, various cell lines were exposed continuously to a
variety of cytotoxic drugs. For testing, the cells and the cytotoxic
compounds were sealed in a closed vessel that also contained
growth medium, sufﬁcient glucose (as a respiratory substrate),
and the Pd phosphor. Untreated cells consume O2 at a constant
rate, whereas drug-treated cells exhibit a diversity of O2 consumption proﬁles (linear or nonlinear).
Oxygen concentration is ﬁt to a linear (Pt compounds and CsA) or
quadratic (dactinomycin, doxorubicin, and tirapazamine) function
of time. Fitting to a higher order, such as cubic or polynomial, can
be applied on the condition that the ﬁt is signiﬁcantly improved
(i.e., r2 signiﬁcantly increased). The rate of respiration k is the negative of the slope of a plot of [O2] versus time as calculated from the
ﬁtting function. The time average respiration rate is proposed as a
characteristic parameter. It is obtained by integrating k over a
well-deﬁned time interval. Then the inhibition I is calculated as
1  hki/hki0 , where hki0 is the average value of k for cells not treated
by drug. It is important to obtain hki and hki0 from measurements on
the same batch of cells. For the most meaningful comparison, the
measurements of [O2] should be done simultaneously (i.e. alternately) on treated and untreated cells.
When I has been measured for a series of drug concentrations D, it
is convenient to ﬁt the results to the two-parameter function,
I = ImaxD / (D + A). The value of I provides a simple and convenient
characterization of drug cytotoxicity. (Other measures of drug cytotoxicity continue to be suggested [28–30].) It also helps to predict the
dosing necessary to shut down respiration of malignant cells and,
thus, may be useful in assessing the efﬁciency of anticancer drugs.
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